title: Rosacea: new and emerging treatments.
abstract: Rosacea is a chronic inflammatory skin condition that negatively impacts patients' quality of life. We sought to review important aspects of the pathogenesis of rosacea and the role of new treatment options in its management. New, emerging treatments show promise; however, quality randomized controlled trials for many of these drugs are lacking. Brimonidine tartrate is an effective newly approved treatment for erythematotelangiectatic rosacea. Topical oxymetazoline has potential for the treatment of erythematotelangiectatic rosacea, with efficacy described in case reports and randomized controlled trials currently underway. Both oral and topical ivermectin have been studied for the treatment of papulopustular rosacea, both showing benefit; however, only topical ivermectin 1 % cream has been studied in randomized controlled trials. As our understanding of the etiology of rosacea continues to evolve, so will our options for therapeutic interventions. Further studies need to be performed to assess the long-term safety and efficacy of these treatments.
authors.affiliation: Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA.
authors.forename: Farah A
authors.initials: FA
authors.lastname: Moustafa
authors.forename: Laura F
authors.initials: LF
authors.lastname: Sandoval
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000279:Administration, Cutaneous; D000068438:Brimonidine Tartrate; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use; D010109:Oxymetazoline / Q000008:administration & dosage / Q000627:therapeutic use; D011788:Quality of Life; D011810:Quinoxalines / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012393:Rosacea / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
chemical_list: D003879:Dermatologic Agents; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D007559:Ivermectin; D010109:Oxymetazoline